Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Active not recruiting 3Terminated 2Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Vomiting 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Postoperative Nausea and Vomiting 1Pain, Intractable 1Oropharyngeal Neoplasms 1Nausea 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Cancer Pain 1Breast Neoplasms 1

Interventions

Cyclophosphamide 4Dexamethasone 3sargramostim 2Bortezomib 2pomalidomide 1isatuximab 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Thalidomide 1Technetium Tc 99m Pyrophosphate 1Technetium 1Registries 1Radiotherapy 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Ketamine 1Filgrastim 1Carboplatin 1Calcium Dobesilate 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Immunoglobulin Light-chain Amyloidosis × Calcium Dobesilate × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡